Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuANTUM-First
2015-004856-24Phase 3Unknown
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Quizartinib arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Status: unknown.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2015-004856-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004856-24.